Maven's proprietary technology and its direct applications address critical needs of the large and expanding worldwide pharmaceutical and diagnostic markets. Its LFIRE™ technology platform represents a new generation of label-free detection of clinically significant biomarkers required in those market sectors represented by discovery and development of targeted drug therapies and their concomitant "theranostic" (a test used to determine choice of drug for therapy). Most importantly, the diagnostics industry, FDA and healthcare reimbursement sector (Medicare and insurance companies) require a new paradigm in drug development and diagnostics for improved predictability and personalized medicine. Maven's LFIRE™ technology is well-suited to the development by diagnostic providers of a new generation of cost-effective true label-free multiplexed diagnostics. LFIRE™ targets those market segments that include:
- Diagnostics
- Pharmaceuticals
- Research
- Industrial
- Public Health and Biodefense
|
 |
